english.prescrire.org > Topics > Advancing healthcare policy > No to EMA's provision of confidential scientific advice to drug companies (11/2017)

Advancing healthcare policy

Via its policy advocacy, Prescrire acts as a force for change in health policies, first and foremost in the interest of patients.

Advancing healthcare policy

No to EMA's provision of confidential scientific advice to drug companies (November 2017)

Prescrire, along with around 20 civil society organisations, has signed a joint declaration drawing attention to potential problems posed by the provision of confidential scientific advice by the European Medicines Agency to pharmaceutical companies, in particular a lowering of the regulatory bar, a risk of regulatory capture, and a total lack of transparency surrounding the activity of European regulatory authorities. Read on...

Paris, 28 November 2017

Prescrire, along with around 20 civil society organisations, has signed a joint declaration drawing attention to potential problems posed by the provision of confidential scientific advice by the European Medicines Agency to pharmaceutical companies, especially a decline in regulatory standards, a risk of institutional capture, and a total lack of transparency surrounding the activity of European regulatory authorities.

> Click here to download the joint declaration (413 Ko)